Geode Capital Management LLC Has $29.97 Million Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Geode Capital Management LLC lifted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 0.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 775,579 shares of the specialty pharmaceutical company’s stock after buying an additional 5,464 shares during the quarter. Geode Capital Management LLC owned about 2.40% of Collegium Pharmaceutical worth $29,974,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of COLL. Foundry Partners LLC acquired a new position in Collegium Pharmaceutical during the 2nd quarter worth $492,000. Penserra Capital Management LLC acquired a new position in shares of Collegium Pharmaceutical during the 3rd quarter worth about $757,000. Squarepoint Ops LLC boosted its stake in Collegium Pharmaceutical by 194.5% during the 2nd quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock valued at $3,553,000 after purchasing an additional 72,874 shares during the period. BOKF NA bought a new stake in Collegium Pharmaceutical during the 2nd quarter valued at approximately $490,000. Finally, Renaissance Technologies LLC grew its holdings in Collegium Pharmaceutical by 8.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock valued at $49,314,000 after buying an additional 113,300 shares during the last quarter.

Collegium Pharmaceutical Stock Up 1.5 %

COLL opened at $29.49 on Friday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $28.75 and a fifty-two week high of $42.29. The company has a market capitalization of $951.05 million, a P/E ratio of 12.71 and a beta of 0.80. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm’s fifty day moving average price is $31.91 and its two-hundred day moving average price is $34.23.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Piper Sandler reissued a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. HC Wainwright raised their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. Finally, StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.